VASCVERSA
LIVE

Serial Number

79436736

Owner

VASCVERSA LIMITED

Filing Date

Sep 30, 2025

Add to watchlist:

No watchlists yet
View on USPTO

VASCVERSA Trademark

Serial Number: 79436736

VASCVERSA is a trademark filed by VASCVERSA LIMITED on September 30, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

VASCVERSA LIMITED (2 trademarks)

63 University Road,

Entity Type: 24

Trademark Details

Filing Date

September 30, 2025

Registration Date

Not Registered

Goods & Services

Stem cells for research purposes; stem cells for scientific purposes; chemicals for use in manufacturing pharmaceuticals; reagents for research purposes; reagents for medical research; reagents for scientific purposes; diagnostic reagents for scientific or research use; cell culture reagents for scientific and research use; blood culture media for scientific use.

Medical and pharmacological research services; stem cell research; scientific services relating to the isolation and cultivation of human tissues and cells; research in the field of cell engineering technology; research in the field of vascular regeneration and repair; research and development of medicines; pharmaceutical drug development services; drug discovery services; development of pharmaceutical preparations and medicines; development of cell therapies; research and development services in the medical field of cell therapy; research and development services in the medical field of vascular regeneration and repair; clinical trials; blood analysis services; gene therapy research; information, advisory and consultancy services in relation to all of the aforesaid services.

Regenerative medicine services; medical services; stem cell therapy services; cell therapy services; cell therapy services for vascular regeneration and repair; cell therapy services relating to the generation of human vascular reparative cells; cell therapy services relating to the injecting, grafting or implanting of cells into patients; medical services relating to the removal, treatment and processing of cells; medical services relating to the removal, treatment and processing of stem cells; stem cell storage; human cell storage; cultured cell bank services for medical transplantation; medical laboratory services for the analysis of samples taken from patients; medical analysis services; services for the testing of blood; medical services relating to the removal, treatment and processing of human blood; information, advisory and consultancy services in relation to all of the aforesaid services.

Pharmaceuticals; drugs for medical purposes; stem cells; pharmaceutical preparations containing stem cells; stem cells for medical purposes; cells for medical use; cell growth media for growing cells for medical use; living cells for medical use; cellular function activating agents for medical purposes; vaccines, reagents for medical use; medical diagnostic reagents; biological tissue cultures for medical purposes; human allograft tissue; tissues for medical use; vascular grafts; sponges for healing wounds.

Medical devices; medical apparatus; medical instruments; apparatus for the regeneration of stem cells for medical purposes; medical devices and apparatus for vascular regeneration and repair; medical devices and apparatus for cell therapy; blood testing equipment; blood testing apparatus; artificial vascular grafts.

Filing History

REFUSAL PROCESSED BY IB
Apr 2, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 17, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 17, 2026 RFRR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 5, 2026 NREP
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 12, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 11, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 4, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 17, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 17, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 13, 2025 REPR